1. Mandai Shintaro, Koide Takaaki, Kitaoka Reo, Matsuki Hisazumi, Suzuki Soichiro, Fujiki Tamami, Ando Fumiaki, Mori Takayasu, Susa Koichiro, Iimori Soichiro, Naito Shotaro, Sohara Eisei, Rai Tatemitsu, Uchida Shinichi. Signature Analyses for Circulating Extracellular Vesicle-Propagated MicroRNAs Reveal VEGFA as a Key Molecule for Vascular Calcification in Chronic Kidney Disease. 第66回日本腎臓学会学術集会総会 2023.06

  2. Matsuki Hisazumi, Mandai Shintaro, Koide Takaaki, Takahashi Naohiro, Yanagi Tomoki, Fujiki Tamami, Mori Yutaro, Ando Fumiaki, Mori Takayasu, Susa Koichiro, Iimori Soichiro, Sohara Eisei, Uchida Shinichi. A brain proteomic signature of chronic kidney disease uncovers blood-brain barrier breakdown via urea-activated matrix metalloproteinase-2. 第66回日本腎臓学会学術集会総会 2023.06

  3. Nakano Yuta, Mandai Shintaro, Naito Shotaro, Fujiki Tamami, Mori Yutaro, Ando Fumiaki, Mori Takayasu, Susa Koichiro, Iimori Soichiro, Sohara Eisei, Rai Tatemitsu, Uchida Shinichi. Impact of Osteosarcopenia on Mortality and CKD Progression: A Prospective Observational Cohort Study. 第66回日本腎臓学会学術集会総会 2023.06

  1. Fujiki T, Ando F, Mandai S, Isobe K, Susa K, Mori T, Nomura N, Sohara E, Rai T, Uchida S.. Tolvaptan and Bardoxolone Methyl Synergistically Activate the Nrf2/HO-1 pathway.. ASN Kidney Week 2019 2019.11.08

  1. Tamami Fujiki, Fumiaki Ando, Kiyoshi Isobe, Takayasu Mori, Koichiro Susa, Naohiro Nomura, Eisei Sohara, Tatemitsu Rai, Shinichi Uchida. Tolvaptan activates Nrf2/HO-1 pathway through PERK phosphorylation. The 52nd Annual Meeting of American Society of Nephrology, Kidney Week 2018 2018.10.26 San Diego

  2. Soichiro Iimori. Evaluation and management of bone metabolism. 第63回日本透析医学会学術集会総会 2018.06.30

  1. Soichiro Iimori, Shotaro Naito, Hidehiko Sato, Naohiro Nomura, Eisei Sohara, Tomokazu Okado, Shinichi Uchida, Tatemitsu Rai. Effects of proteinuria reduction on kidney function, mortality and cardiovascular risk in newly visiting CKD patients in Japan : the CKD-ROUTE study. The 6th CKD Frontier Meeting 2017.02.25 Nagoya, Japan

  1. Soichiro Iimori, Hidenori Nishida, Tomokazu Okado, Tatemitsu Rai, Shinichi Uchida, Sei Sasaki.. Anemia management and cardiovascular risk in newly visited CKD patients in Japan. The 14th Asian Pacific Congress of Nephrology 2014.05.15 Tokyo

  1. Soichiro Iimori, Sotaro Naito, Kayoko Eto, Eisei Sohara, Tomokazu Okado, Yumi Noda, Tatemitsu Rai, Shinichi Uchida, Sei Sasaki.. The effect of Educational Hospitalization (EH) on the progression of CKD.. 1st Chronic Kidney Disease Frontier Meeting 2012.02 Nagoya

  1. Soichiro Iimori, Sei Sasaki, Yusuke Tsukamoto. . Diagnostic usefulness of bone mineral density in predicting vertebral fracture and abdominal aortic calcification in CKD stage 5D patients.. The 43rd Annual Meeting of American Society of Nephrology. 2010.11 Denver

  1. Soichiro Iimori, Yoshihiro Mori, Tamaki Kuyama, Shigeru Takada, Tomoki Asai, Michio Kuwahara, Sei Sasaki, Yusuke Tsukamoto.. Bone mineral density (BMD) and fracture risk in CKD 5D patients.. The 42nd Annual Meeting of American Society of Nephrology 2009.10 San Diego

  1. Fujiki T, Ando F, Mandai S, Isobe K, Susa K, Mori T, Nomura N, Sohara E, Rai T, Uchida S. Tolvaptan activates the Nrf2/HO-1 pathway through PERK phosphorylation. The 23nd International Joint Conference on Cardiovascular and Metabolic diseases 2019.12.14

  2. Fujiki T, Ando F, Isobe K, Susa K, Mori T, Nomura N, Sahara E, Rai T, Uchida S. Tolvaptan activates the Nrf2/HO-1 pathway through PERK phosphorylation. The 62nd Annual Meeting of the Japanese Society of Nephrology 2019.06.22 Nagoya

To the head of this page.▲